Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2014 | New therapies for mantle cell lymphoma

Umberto Vitolo • 5 Dec 2014
ASH 2014
Mantle Cell Lymphoma Ibrutinib Lenalidomide

Prof Umberto Vitolo (Città della Salute e della Scienza di Torino, Turin, Italy) at the 2014 American Society of Hematology (ASH) Annual Meeting discusses new therapies for mantle cell lymphoma, including biologic approaches with lenalidomide plus rituximab, ibrutinib and ABT-199.

More from Umberto Vitolo

Outcomes from the EPCORE DLBCL-3 trial: fixed-duration epcoritamab in elderly patients with DLBCL
2:36
Outcomes from the EPCORE DLBCL-3 trial: fixed-duration epcoritamab in elderly patients with DLBCL
Umberto Vitolo • 12 Jun 2026
Will frontline DLBCL treatment become subtype-specific rather than a one-regimen-fits-all approach?
1:12
Will frontline DLBCL treatment become subtype-specific rather than a one-regimen-fits-all approach?
Umberto Vitolo • 12 Jun 2026
Results from the Phase III FRONTMIND study: tafasitamab, lenalidomide, and R-CHOP in frontline DLBCL
2:16
Results from the Phase III FRONTMIND study: tafasitamab, lenalidomide, and R-CHOP in frontline DLBCL
Umberto Vitolo • 12 Jun 2026
Fixed-duration epcoritamab with BR for 1L treatment of FL: 3-year results from EPCORE NHL-2 arm 3
1:39
Fixed-duration epcoritamab with BR for 1L treatment of FL: 3-year results from EPCORE NHL-2 arm 3
Umberto Vitolo • 5 Dec 2025

Related Videos

Community lymphoma management: which patients should be prioritized for specialist referral?
1:16
Community lymphoma management: which patients should be prioritized for specialist referral?
Nirav Niranjan Shah • 10 Sep 2026
Lessons from the US: NCCN guidelines enable early access to novel MCL treatments
1:00
Lessons from the US: NCCN guidelines enable early access to novel MCL treatments
Yucai Wang • 10 Sep 2026
Lessons from the US: treatment access and patient-guided treatment selection in MCL
0:51
Lessons from the US: treatment access and patient-guided treatment selection in MCL
Elise Chong • 10 Sep 2026
BTKi selection in R/R MCL: implications for sequencing non-covalent BTKis
1:23
BTKi selection in R/R MCL: implications for sequencing non-covalent BTKis
Yucai Wang • 10 Sep 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals